Last reviewed · How we verify

RSVpreF (rsvpref)

Pfizer · FDA-approved active Quality 45/100

RSVpreF, developed by Pfizer Inc., is a marketed drug used to prevent RSV lower respiratory tract disease in high-risk neonates, infants, and children. It is a monoclonal antibody that targets the RSV virus. The drug has shown significant clinical differentiation in its ability to prevent severe RSV disease. Its commercial significance is evident in its high revenue of $63.6 billion. With 164 publications and 26 trials, RSVpreF has a strong clinical foundation. The drug's mechanism of action involves binding to the RSV F protein, preventing the virus from entering host cells. As a marketed product, RSVpreF has established itself as a key player in the prevention of RSV disease.

At a glance

Generic namersvpref
SponsorPfizer
Drug classMonoclonal antibody
TargetRSV F protein
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results